Posted by Michael Wonder on 28 Sep 2016
Decision to not accept any proposals for the insulin glargine request for proposals
28 September 2016 - PHARMAC has decided not accept any proposals for the supply of insulin glargine following consideration of responses to the request for proposals for insulin glargine issued on 22 February 2016.
This means that there will be no changes to the listing of the current brand of insulin glargine (Lantus) in Section B and Part II of Section H of the Pharmaceutical Schedule as a result of the request for proposals.
